Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CTRC | Q99895 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430966 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2207361 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2207365 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2208793 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL12434536 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL6761452 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2207391 | 0.86 | ALDH1A1 (0.63) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2207748 | 0.86 | ALDH1A1 (0.63) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL2207396 | 0.86 | ALDH1A1 (0.63) | ALDH1A1HPGDGAAHSD17B10ALDH2 | |
| SCHEMBL6763352 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HPGDGAAHSD17B10ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | claimed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-9309215-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309215-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20140228434-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | UCB PHARMA GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228434-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | UCB PHARMA GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8742140-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8742140-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-7982058-B2 | Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof | UCB PHARMA GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| EP-2281801-A1 | Process for obtaining 3,3-diphenylpropylamines | Ragactives, S.L.U. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2011012584-A1 | PROCESS FOR OBTAINING 3,3-DIPHENYLPROPYLAMINES | RAGACTIVES, S.L.U. (ES) | 2011-02-03 | — | — | WO | disclosed |
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2009-07-30 | — | — | US | disclosed |
| EP-2027103-A1 | NEW CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007144097-A1 | NEW CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144097-A1 | NEW CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1289929-B1 | SHORTENED SYNTHESIS OF 3,3-DIARYLPROPYLAMINE DERIVATIVES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192224-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | CYP1B1, NISCH, HSD17B7 | ALDH1A1 780/4885HPGD 498/4885GAA 818/4885 |
| US-20140228434-A1 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF | CYP1B1, NISCH, HSD17B7 | ALDH1A1 780/4885HPGD 498/4885GAA 818/4885 |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | ADH1C, NISCH, ADH1A | ALDH1A1 422/4885HPGD 2388/4885GAA 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.